Alex's Lemonade Stand grants support BCM childhood cancer researchers
HOUSTON -- (July 9, 2012) -- Three Baylor College of Medicine researchers received support totaling $500,000 from the nonprofit organization Alex's Lemonade Stand Foundation for their work to find more effective treatments for childhood cancer.
Innovation grants were awarded to Dr. Margaret Goodell, professor of pediatrics hematology/oncology, and Dr. Leonid Metelitsa, associate professor of pediatrics hematology/oncology. Dr. Meenakshi Hegde, a clinical postdoctoral fellow in pediatrics hematology/oncology, received a Young Investigator Award.
"We're grateful for the support of Alex's Lemonade Stand. They are an important partner in helping us reach our goal of finding better, more effective ways to treat childhood cancer that could eventually lead to a cure," said Dr. David Poplack, professor of pediatric oncology at BCM and director of the Texas Children's Cancer Center.
Role of gene LYL1
The grant funding to Goodell will support her research on the role the gene LYL1 plays in T-Cell ALL, one of the most frequent types of childhood leukemia. Researchers hypothesize that the overexpression of LYL1 plays a key role in generating T-ALL precursor cells. The research will examine in mice the mechanism through which LYL1 exerts its effects, with the hope to eventually develop strategies to interfere with the role of the gene in malignancy development.
T (NKT) cells
The grant to Metelitsa will help fund his ongoing research to understand how special cells called natural killer T (NKT) cells can be used to suppress neuroblastoma tumor growth. The project will use NKTs from neuroblastoma patients and genetically modify them with two proteins that have been shown in mice to protect and enhance the NKT cells' anti-tumor effectiveness.
"Neuroblastoma is a common solid tumor in children. About 60 percent of children with high-risk neuroblastoma are not cured, so new treatment strategies based on the understanding of body's immune system are needed to treat this disease," Metelitsa said.
Targeting two proteins
The Young Investigator Award to Hegde will support research that targets two proteins simultaneously that play a role in recurrent glioma brain tumors. Researchers will genetically engineer T-cells to become both HER2 and IL-13Ra2-specific and test in the lab and in animal models, if this results in better tumor control over targeting one protein only. High-grade gliomas constitute nearly 20 percent of all childhood brain tumors and even with aggressive therapy do not respond well to treatment. Expected survival rarely exceeds two years, and less than 25 percent of patients survive five years from diagnosis, Hegde said.
"It has always been our goal to find better treatments and cures for all kids with cancer by funding the best research possible," said Jay Scott, co-executive director of the foundation.
- May 14, 2013
- 'Off-the-shelf' virus-specific T-cells fight viral infections in stem cell transplant patients
Viral infections present deadly threats to patients who have received donor blood, marrow and cord stem cells transplants and are immune deficient while their transplants begin to work.
- April 9, 2013
- BCM major part of new pediatric cancer Dream Team initiative
Baylor College of Medicine is part of a Dream Team of childhood cancer researchers that will focus on melding the fields of genomics and immunotherapy to advance treatment for pediatric cancer.
- March 28, 2013
- Wipe Out Kids’ Cancer donates $75,000 to Texas Children’s Cancer Center
The grant will be used to fund a research project on neuroblastoma, an aggressive pediatric cancer that strikes approximately 650 children a year in the U.S., usually before age 5.
- March 1, 2013
- Fundraiser supports pediatric cancer in South Texas
Actor Diego Boneta, top right, helped raised $90,000 for the Vannie Cook Children’s Cancer Clinic in South Texas at the 2013 Radiothon.
- February 27, 2013
- Hematology-oncology faculty members receive renewed NIH funding to enhance T cell therapy for cancer
Hematology-oncology faculty members from the Center for Cell and Gene Therapy (CAGT) have received a $11.3 million renewal grant from the National Institutes of Health to advance the development of more effective and less toxic targeted T cell therapies for children and adults with cancer.
- February 1, 2013
- Grant funds developmental therapeutics program
A five-year, $1.75 million grant from Alex’s Lemonade Stand Foundation was awarded to Texas Children’s Cancer Center to establish the Developmental Therapeutics Center of Excellence.
- January 4, 2013
- Houston Radio Host Kevin Kline Completes his 62,000 Step Stair Run
Kevin Kline, Houston morning radio host on The New 93Q, ran 62,000 Stairs at Constellation Field, home of the Sugar Land Skeeters Baseball team in Sugarland, TX.
- December 12, 2012
- Vegetable compound could become ingredient to treating leukemia
A concentrated form of a compound called sulforaphane found in broccoli and other cruciferous vegetables has been shown to reduce the number of acute lymphoblastic leukemia cells in the lab setting, said researchers at Baylor College of Medicine. The findings appear in the current edition of PLOS ONE.
- December 11, 2012
- Montblanc and Texas Children’s Cancer Center encourage families to give a gift that counts this holiday season
Montblanc and Texas Children’s Cancer Center have launched a new initiative allowing people across the United States to show their support for children and adolescents fighting cancer by providing an opportunity to purchase a specially designed bracelet to be given to the parent of a pediatric cancer patient this holiday season.
- December 6, 2012
- Q&A: Sharon Plon on Baylor College of Medicine's First Year of Clinical Exome Sequencing
As a member of Baylor College of Medicine's Whole Genome Laboratory management committee, Sharon Plon has been a leader in establishing Baylor's clinical exome sequencing diagnostic test, which was launched last November.
This is part one of a two-part interview. Part two will appear in next week's issue.